89422GAA5
Travere Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is FDA-approved to slow kidney function decline in adults with a rare kidney disease called primary IgA nephropathy, and the company also sells Thiola and Thiola EC for the kidney stone condition cystinuria. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for the rare metabolic disorder classical HCU.
CONVERTIBLEUnderlying: TVTXCUSIP: 89422GAA5HealthcareUS1 derivative reporter
2.25% Convertible Senior Notes due March 1, 2029
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
